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Abstract
Thrombophilia can be defined as a predisposition to form clots inappropriately. Thrombotic events
during infancy and childhood are increasingly recognized as a significant source of mortality and
morbidity. The predisposition to form clots can arise from genetic factors, acquired changes in the
clotting mechanism, or, more commonly, an interaction between genetic and acquired factors.
Since the turn of the last century, there has been extensive research focusing on both the genetic
and acquired causes of thrombophilia, with particular focus on clotting events in the venous
circulation. This review describes clinically relevant aspects of genetic venous thrombophilia, which
include well-established, lesser known, and suggested causes of inherited thrombophilias.
Background
Thrombophilia can be defined as a predisposition to form
clots inappropriately. Thrombotic events are increasingly
recognized as a significant source of mortality and mor-
bidity [1]. The predisposition to form clots can arise from
genetic factors, acquired changes in the clotting mecha-
nism, or, more commonly, an interaction between genetic
and acquired factors [2]. A hereditary thrombophilia
results when an inherited factor, such as antithrombin or
protein C deficiency, requires interaction with compo-
nents that are inherited or acquired before onset of a clin-
ical disorder [3]. A homozygous abnormality or
combination of two or more heterozygous abnormal fac-
tors can lead to clinically apparent thrombotic disorders
at an early age. However, milder heterozygous traits, when
existing alone, are more often discovered by laboratory
investigation. [3]. Since the turn of the last century, there
has been extensive research focusing on both the genetic
and acquired causes of thrombophilia, with particular
focus on clotting events in the venous circulation. This
paper will focus on clinically relevant aspects of genetic
venous thrombophilia. While there is evidence for adverse
outcomes of pregnancy associated with thrombophilia,
an in-depth discussion of that area is beyond the scope of
this article.
Review of clotting and fibrinolysis
In 1856, Rudolf Virchow proposed a hypothesis to
explain the etiology of pulmonary emboli, which lead to
the understanding of the three primary causes of venous
and arterial thrombosis: stasis, injury to the vessel wall
and abnormalities in the circulating blood. Subsequently,
numerous investigators elucidated the concept of a hemo-
static balance between fibrin formation and fibrin disso-
lution.
As our insight into the hemostatic and fibrinolytic path-
ways has developed it has become apparent that there are
specific factors that can create an imbalance in the clotting
process and thus lead to thrombosis as originally sug-
gested by Virchow. An understanding of both the coagula-
tion and fibrinolysis pathway has helped to determine
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specific factors that can cause such an imbalance in
hemostasis.
Coagulation cascade
The coagulation and fibrinolytic systems are two separate
but linked enzyme cascades that regulate the formation
and breakdown of fibrin. The blood clotting system or
coagulation pathway, like the complement system, is a
proteolytic cascade. Each enzyme of the pathway is
present in the plasma as a zymogen (an inactive form),
which, on activation, undergoes proteolytic cleavage to
release the active factor from the precursor molecule. The
coagulation pathway functions as a series of positive and
negative feedback loops which control the activation
process. The ultimate goal of the pathway is to produce
thrombin, which can then convert soluble fibrinogen into
fibrin, which forms a clot. The generation of thrombin can
be divided into three phases: the intrinsic and extrinsic
pathways that provide alternative routes for the genera-
tion of factor X, and the final common pathway which
results in thrombin formation.
Coagulation is initiated when factor VIIa binds to tissue-
factor (TF) on the surface of endothelial cells and mono-
cytes at sites of vascular injury. The TF-factor VII complex
activates factor IX and X to factors IXa and Xa, respectively.
Factor Va and Xa, together, activate prothrombin to
thrombin. Thrombin has multiple prothombotic roles: it
cleaves soluble fibrinogen to insoluble fibrin that will
eventually form the hemostatic plug, and activates factors
V, VIII, XI and XIII. Thrombin also acts to produce an anti-
coagulant effect by forming an enzyme complex with
thrombomodulin to activate protein C. The tissue factor-
VIIa complex is rapidly inactivated by the TF pathway
inhibitor.
Natural inhibitors of coagulation
Activated coagulation factors are serine proteases, and
their activity is modulated by several naturally occurring
plasma inhibitors. The most important inhibitors of the
blood coagulation system are antithrombin, protein C,
and protein S [4]. An inherited deficiency of one of these
three proteins is found in about 15% of patients who
present with venous thrombosis before the age of 45 [5].
Antithrombin (AT) is a serine proteinase inhibitor that
plays a significant role in the process of coagulation by
interaction with its co-factor, heparin. Antithrombin inac-
tivates thrombin directly, and also inactivates factors IX, X
and XI by forming a covalent complex. Inhibition of most
of the factors is slow; however, the process can be acceler-
ated at least 1000 fold by the binding of heparin and
heparin-like compounds to AT [6]. Protein C is activated
by thrombin, a process greatly enhanced by the interac-
tion of thrombin with thrombomodulin. Activated pro-
tein C proteolytically inactivates factors Va and VIIIa on
the platelet and endothelial cell surface and hence serves
to block thrombin generation and the subsequent steps in
coagulation. Protein C requires protein S, another vitamin
K dependent molecule as a co-factor. The imbalance
between reduced inhibitors of coagulation and/or
increased activation of coagulation factors lead to throm-
bosis [4].
Fibrinolysis
Specific enzymes are involved in the removal of blood
clots from the circulation and the turnover of extracellular
matrix proteins. One of the most important enzymes in
this setting is plasmin. The main role of plasmin is to
degrade fibrin, which makes up the structural basis of a
blood clot. Plasmin exists in its inactive form as plasmino-
gen; the activation of plasminogen is mediated by serine
enzymes known as tissue-type plasminogen activator (t-
PA) and urokinase (u-PA). The proteolytic activity of t-PA
and u-PA is, in turn, regulated by specific protease inhibi-
tors, plasminogen activator inhibitor (PAI)-1 and PAI-2.
Plasminogen deficiencies can also lead to thrombophilia
in patients.
Historical Background
A familial component of venous thrombosis was first fully
recognized in the 1960s when reduced levels of AT were
shown to be associated with recurrent thrombosis in a
family [7]. Since this discovery, multiple studies have
shown almost 250 different mutations for AT deficiency
and the risks associated with this disorder. The next step
in finding other causes of inherited thrombophilia fol-
lowed 16 years later with the discovery of protein C defi-
ciency [8]. The study by Broekman et al in 1983 of three
Dutch families provided further understanding of this
deficiency and confirmed the autosomal dominant inher-
itance pattern. That study of protein C demonstrated that
inherited thrombophilia was a polygenic disorder with
variable expressivity. This was followed a few years later
with the discovery of an inherited deficiency of the co-fac-
tor for protein C, protein S. [9]. All three of these proteins,
AT, protein C and protein S, play a role in the downregu-
lation of coagulation. Deficiencies of these proteins result
in an increased generation of thrombin and a predisposi-
tion to thrombosis.
Further confirmation of the multiple genetic factors for
increased thrombotic risk came with the description of
activated protein C-Resistance (APC-R) in 1993, and dra-
matically changed the diagnosis and management of
venous thrombotic events. Dahlback et al described a
large family from southern Sweden who demonstrated
thrombosis in males and females throughout several gen-
erations and showed an autosomal dominant pattern of
inheritance [10]. They observed a significant prolongationThrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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of the activated partial thromboplastin time (aPTT) in the
normal plasma following the addition of APC (APC inac-
tivates factor Va and factor VIIIa, thereby decreasing avail-
able thrombin). In contrast, plasma from the affected
family showed a lack of significant prolongation of the
APTT. The authors concluded that there was an abnormal-
ity in the protein C/protein S regulatory system. Subse-
quently, this abnormality was identified as a single amino
acid substitution in one of the substrate proteins for APC:
Factor V. This mutation was later characterized by Bertina
and colleagues at the University of Leiden [11]. The rapid-
ity with which the genetic mutation was identified follow-
ing the phenotypic observation of APC-R is an example of
the dramatic shift to gene-based diagnosis of disease.
Dahlback et al subsequently reported that as many of 15%
of the population in southern Sweden carried the factor V
Leiden (FVL) gene. The identification of FVL significantly
changed the way clinicians and laboratories approach the
diagnosis of thrombophilia.
Early discoveries of genetic prothrombotic risk factors
involved gene mutations that resulted in decreased con-
centrations or function of certain coagulation proteins.
Eventually studies showed that elevations of proteins
could also convey a risk for thrombophilia. For example,
elevated Factor VIII has been described as a risk factor for
recurrent venous thrombosis, especially when it is familial
trait rather than an acute phase reactant [12]. Various
other factors for congenital thrombophilia have been
described including hyperhomocysteinemia, elevated
lipoprotein and dysfibrinogenemia, to name a few. Stud-
ies have also shown that these factors may co-exist with
other inherited defects leading to thrombophilia. As a
consequence, there has been a marked change in the eval-
uation and management of thrombophilia in recent years.
Table 1 provides a listing of established, rare and indeter-
minate factors causing genetic thrombophilia [13].
Epidemiology
Venous thrombosis has an overall annual incidence of < 1
in 1000. It is rare in the pediatric population, with rates of
deep vein thrombosis of about 1 in 100,000 [1] and
increases in frequency in older patients. While significant
advances have been made in understanding congenital
thrombophilias, there may still be many more heritable
forms of thrombophilia as yet undiscovered. Thus, it is
not possible to determine the true prevalence of congeni-
tal thrombophilia.
Pediatric disorders associated with genetic thrombophilia
include neonatal purpura fulminans, renal vein thrombo-
sis, vena cava thrombosis and hepatic venous thrombosis.
Pulmonary embolism, Legg Calve Perthes and cerebral
palsy have all been linked to genetic thrombophilia [13].
Complete deficiency of protein C or S (homozygous indi-
viduals) cause neonatal purpura fulminans and dissemi-
nated intravascular coagulation with an incidence of
about 1 in 16,000–360,000 [14]. Table 2 shows the prev-
alence of genetic defects among Caucasians with venous
thrombosis [15].
A summary of the results from case series and case-control
studies in caucasian children with venous thrombosis is
presented in Table 3[16].
Thromboembolic events cause significant mortality and
morbidity among patients of all ages. Possibly owing to
the lower concentrations of antithrombin, heparin cofac-
tor II, and protein C, along with a reduced fibrinolytic
capacity, neonates are at greater risk of thromboembolic
complications than older children [16]. The incidence of
vascular accidents decreases significantly after the first
year of life, with a second peak during puberty and adoles-
cence, again associated with reduced fibrinolytic activity.
The increased understanding of thrombophilias at a
molecular level that has developed over the past 40 years
has lead to conceptual changes on how to diagnose and
manage the disorder. Studies have been done in various
populations to understand the inheritance patterns and
risks for individuals with an inherited thrombophilia.
Familial thrombosis was originally considered an auto-
somal dominant disorder with varying expression and
penetrance. However, more recent studies suggest that
congenital thrombophilia may in fact be the result of the
combination of two or more gene defects in a family [17].
The following sections will discuss the various congenital
thrombophilias and the degree to which each of these dis-
orders puts an individual at risk for a thromboembolic
event.
Specific types of inherited thrombophilias
1. Factor V Leiden
In 1994, Bertina et al first described a defect in the factor
V gene that makes it less susceptible to inactivation by
activated protein C (APC). The following year, Kalafatis et
al showed the mechanism of inactivation of the mem-
brane bound profactor Va is an ordered event. Factor Va is
sequentially cleaved at Arg506 and at Arg306 and Arg679
by activated protein C [18]. They suggested that the pep-
tide bond cleavage at Arg506 facilitates the exposure of
the subsequent cleavage sites at Arg306 and Arg679. At
around the same time, Shen and Dahlback et al showed
that factor V is also a cofactor in the inactivation of factor
VIIIa by APC [19].
The understanding of factor V inactivation was almost
immediately followed by reports on how activated pro-
tein C in patients' plasma failed to prolong the activated
partial thromboplastin time, hence the term "activated
protein C resistance" was developed [20].Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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Further studies have shown that most patients with acti-
vated protein C resistance have a factor V allele that is
resistant to the proteolytic effect of protein C. A transition
(guanine to adenine) at nucleotide 1691 (G1691) results
in the replacement of arginine by glutamine. This gene
product, called factor V Leiden, also known as factor V
Q506 or Arg506Gln, is named after the city in the Nether-
lands that it was first identified in. Factor V Leiden is a var-
iant of the normal gene and is not susceptible to cleavage
at position 506 by activated protein C. The consequence
of this is a hypercoagulable state as more factor Va is avail-
able within the prothrombinase complex, thereby increas-
ing the generation of thrombin. Factor V is also thought to
be a cofactor, along with protein S, in supporting the role
of activated protein C in the degradation of factors Va and
VIIIa. Thus, lack of this cleavage product decreases the
anticoagulant activity of activated protein C.
Several mutations at the Arg306 residue in factor V have
been described in patients with a history of thrombosis.
These include replacement of Arg306 with threonine (fac-
tor V Cambridge) [21] or with glycine (in Hong Kong Chi-
nese)[22]. Occasionally, patients have been described
who have heterozygous APC resistance due to the factor V
Leiden mutation and type I factor V deficiency [23]. The
plasma of these individuals manifests severe APC resist-
ance in activated partial thromboplastin time assays, sim-
ilar to that seen in patients with homozygous factor V
Leiden. These patients appear to be more thrombosis
prone than their heterozygous relatives with factor V Lei-
den alone, suggesting that the clinical phenotype is simi-
lar to patients who are homozygous for factor V Leiden.
Factor V Leiden and risk of thrombosis
There are multiple studies showing evidence for factor V
Leiden as a cause of deep vein thrombosis (DVT) among
the Caucasian population. The major clinical manifesta-
tion is deep vein thrombosis with or without pulmonary
embolism. There is also evidence that the factor V Leiden
mutation, presumably due to thrombosis of placental ves-
sels, may play a role in some cases of unexplained recur-
rent pregnancy loss.[24]
Svennson and Dahlback studied 34 families with the Fac-
tor V506 Arg to Gln mutation and found an increased life-
time risk of venous thrombosis. By age 50, at least 25% of
those affected had experienced at least one thrombotic
event. The Leiden Thrombophilia Study by Koster et al in
the Netherlands provided a population-based case control
study to assess the prevalence of this disorder. APC-R was
found in 21% of those who had a history of thromboem-
bolism compared with 5% of controls. Overall, the rela-
Table 1: Causes of genetic thrombophilia
Established genetic factors Rare genetic factors Indeterminate factors
Factor V Leiden Dysfibrinogenemias Elevated Factor VIII
Prothrombin G20210A Hyperhomocysteinemia Elevated Factor IX
Protein C deficiency Elevated Factor XI
Protein S deficiency Plasminogen deficiency
Antithrombin deficiency Tissue plasminogen activator
Elevated lipoprotein a
Factor VII
Factor XII
Platelet glycoprotein
Plasminogen activator inhibitor
Heparin cofactor II
Thrombomodulin
Histidine-rich glycoprotein
Table 2: Prevalence of genetic defects among Caucasians [15]
Incident VTE (%) Recurrent VTE (%) Normal population Relative thrombotic risk
Activated Protein C resistance (Factor V Leiden) 20 40–50 3–7 3–7 heterozygotes 50–100 
homozygotes
Prothrombin G20210A mutation 3–8 15–20 1–3 2–8 heterozygotes
Antithrombin deficiency 1–2 2–5 0.02–0.04 5
Protein C deficiency 2–5 5–10 0.2–0.5 6–10
Protein S deficiency 1–3 5–10 0.1–1 2Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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tive risk for a thromboembolic event was increased seven-
fold with heterozygous individuals. They further studied
individuals who were homozygous for factor V Leiden
mutation and found an 80-fold increase in the lifetime
risk for a thrombotic problem. It was subsequently esti-
mated that homozygous individuals can be expected to
experience at least one venous thromboembolic event in
their lifetime [20]. This is supported by a study of 306
family members from 50 Swedish families, which found
40 percent of homozygotes had an episode of venous
thrombosis by age 33, compared to 20 percent of hetero-
zygotes and 8 percent of normals.
Ridker et al published a study in 1997 based on 4047
American men and women participating in the Physi-
cian's Health Study and the Women's Health Study. The
study found a 12 percent incidence of heterozygosity for
the factor V Leiden mutation in patients with a first con-
firmed deep vein DVT or pulmonary embolism compared
with 6 percent in controls [24]. The incidence reached 26
percent in men over the age of 60 with no identifiable pre-
cipitating factors.
Factor V Leiden in different populations
The prevalence of heterozygosity for the factor V Leiden
mutation in Europeans, Israeli, Arab, Canadian and
Indian populations, ranges from 1 to 8.5 percent with
most European studies reporting overall rates between 5
and 8 percent. The prevalence is highest in Greece, Swe-
den, and Lebanon where it approximates 15 percent in
some areas. On the other hand, the mutation is appar-
ently not present in African Blacks, Chinese, or Japanese
populations [25].
Although possibly influenced by a selection bias, the life-
time probability of developing thrombosis is considera-
bly less in heterozygotes with the factor V Leiden
mutation than in patients with the less common inherited
thrombophilias. This was illustrated in a report which
compared the risk for thrombosis in a 150 Italian individ-
uals with inherited thrombophilia due to factor V Leiden
in relation to those with antithrombin, protein C, or pro-
tein S deficiency [26]. The lifetime probability of develop-
ing thrombophilia was 8.5 times higher for carriers of
protein S deficiency, 8.1 for antithrombin deficiency, 7.3
for protein C deficiency, and 2.2 for factor V Leiden when
compared to controls.
An extensive review of different populations was con-
ducted by Rees et al in 1995 where they collected genetic
data from 1690 unrelated individuals from 24 different
populations [27]. Unfortunately, the study does not clar-
ify the methods for the selection of the individuals nor the
inclusion/exclusion criteria. The study does provide a
breakdown for both heterozygotes and homozygotes of
the factor V Leiden mutation and shows significant differ-
ences among populations. The study confirms a higher
prevalence of the mutation among Europeans compared
to individuals from other parts of the world.
2. Prothrombin gene mutation
In 1996, Poort et al described single amino acid genetic
variation in the 3' untranslated region of the gene that
codes for prothrombin. Prothrombin (factor II) is the pre-
cursor to thrombin, the end-product of the coagulation
cascade. Prothrombin has procoagulant, anticoagulant
and antifibrinolytic activities and thus a disorder involv-
ing prothrombin results in multiple imbalances in
hemostasis. A report published in 1996 based on 28 fam-
ilies from the Netherlands with established venous
thromboembolism identified a substitution of guanine to
adenine at nucleotide 20210 in the 3' untranslated region
of the prothrombin gene [28]. Linkage studies performed
in 397 individuals from 21 Spanish families have pro-
vided further evidence that a quantitative trait locus
(G20210) in the prothrombin gene influences pro-
thrombin activity levels and susceptibility to thrombosis
[29].
Prothrombin gene mutation and risk of thrombosis
The prothrombin G20210A gene mutation is associated
with an elevated risk of deep vein thrombosis, although to
a lesser degree than factor V Leiden is. The Leiden Throm-
bophilia Study, a population-based study demonstrated a
prevalence of the G20210A allele among healthy carriers
to be 6.2% among venous thrombosis patients and 2.3%
among healthy matched controls. The study also showed
that among heterozygotes with the prothrombin gene
Table 3: The prevalence of risk factors among caucasian children with venous thrombosis: a summary of the results from case series 
and case-control studies[16].
Controls Patients Odds ratio (95% CI)
Factor V Leiden 15/370 83/261 11 (6.2–19.7)
Prothrombin G20210A 4/370 11/261 4.1(1.3–12.8)
Protein C deficiency 3/370 24/261 12.4 (3.7–41.6)
Protein S deficiency 3/370 15/261 7.5 (2.1–26)
Antithrombin deficiency 0/370 9/261 --
Lipoprotein a > 30 mg/dl 19/370 78/261 7.2Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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mutation, 87% of thrombosis patients in the study had
prothrombin activity levels that were > 1.15 U/ml,
whereas only 23% of healthy individuals had levels that
were elevated to this degree [20].
In 1996 Poort et al compared individuals from 28 families
from the Netherlands with venous thrombosis with 100
normal adults and showed an odds ratio of 2.8 (95% CI
1.4–5.6) for those with the G20210A allele. Their results
demonstrated that elevated prothrombin and the pres-
ence of allele G20210A were both risk factors for throm-
bosis. Heterozygous carriers were shown to have 30
percent higher plasma prothrombin levels than normal
individuals. There is wide variability in geographic distri-
bution of the prothrombin gene mutation. The propor-
tion of white individuals heterozygous for the allele varies
from 0.7 percent to 6.5 percent, with the highest preva-
lence rates reported in Spain [30].
A review of data from 11 centers in Europe found a range
of 0.7 to 4.0 percent, with the prevalence in southern
Europe being almost twice as high as northern Europe
(3.0 versus 1.7 percent). The prothrombin gene mutation
so far has been shown to be extremely rare in the non-
white (black or Asian) population. Zilvelin et al postu-
lated a "founder effect", suggesting the mutation probably
occurred after the divergence of Africans from non-Afri-
cans and of Caucasians from Mongoloid subpopulations
[31].
3. Protein C deficiency
Protein C deficiency is less common than either the factor
V Leiden or the prothrombin G20210A gene mutation
with prevalence in Caucasians estimated to be 0.2–0.5%
[2]. Protein C deficiency is inherited in an autosomal
dominant manner and is associated with familial venous
thrombosis. The gene for protein C is located on chromo-
some 2 (2q13–14) and appears to be closely related to the
gene for factor IX [32]. The primary effect of activated pro-
tein C (APC) is to inactivate coagulation factors Va and
VIIIa, which are necessary for efficient thrombin genera-
tion and factor X activation [33]. The inhibitory effect of
APC is markedly enhanced by protein S, another vitamin
K-dependent protein.
Two major subtypes of heterozygous protein C deficiency
(Type I and Type II) have been delineated using immuno-
logic and functional assays. Over 160 different gene
abnormalities have been associated with the two subtypes
[34].
Type I deficiency – The type I deficiency state is more com-
mon. Most affected patients are heterozygous, having a
reduced plasma protein C concentration at approximately
50 percent of normal in both immunologic and func-
tional assays [35]. More than half of the mutations identi-
fied so far are missense and nonsense mutations. Other
types of mutations include promoter mutations, splice
site abnormalities. in-frame deletions, frameshift dele-
tions, in-frame insertions, and frameshift insertions [34].
There is marked phenotypic variability among patients
with heterozygous type I protein C deficiency. Similar
mutations have been found among symptomatic and
asymptomatic individuals. This finding suggests that the
nature of the protein C gene defect alone does not explain
the phenotypic variability.
Type II deficiency – Individuals with the type II deficiency
state have normal plasma protein C antigen levels with
decreased functional activity. A variety of different point
mutations affecting protein function have been identified
in this disorder [34].
Protein C and risk of thrombosis
Although the clinical manifestations of protein C are sim-
ilar to those of antithrombin deficiency, there are some
unique features of protein C deficiency. In a study of 11
infants in Denver, Colorado in 1988, Manco-Johnson et
al suggested that homozygotes can develop a severe
thrombotic tendency in infancy characterized as purpura
fulminans [36]. Heterozygotes for protein C deficiency
have an increased risk of developing warfarin-induced
skin necrosis [37]. Protein C deficiency has been impli-
cated in adverse pregnancy outcomes such as DVT, preec-
lampsia, intrauterine growth restriction and recurrent
pregnancy loss [38].
Family studies from the Netherlands and the US have
shown that family members who are PC deficient are at an
8–10 fold increased risk of venous thrombosis, and, by
age 40, 50% or more will have experienced a thrombotic
event [39,35]. The initial episode of venous thromboem-
bolism in patients with protein C deficiency is apparently
spontaneous in approximately 70 percent of cases. The
remainder of the cases suggest that other genetic or
acquired factors are involved in the presentation of
thrombotic events in this population. Further studies in
the Netherlands showed that most patients are asympto-
matic until their early twenties, with increasing numbers
experiencing thrombotic events as they reach the age of 50
[40]. Lensen et al concluded that the median age at onset
for a thrombotic event and the risk of thrombosis is simi-
lar in both protein C deficiency and factor V Leiden (APC
resistance). Approximately 60 percent of affected individ-
uals develop recurrent venous thrombosis and about 40
percent have signs of pulmonary embolism.
The first case-control study looking at protein C deficiency
was conducted by Heijboer et al in 1990 who did a study
on 277 Dutch patients and 138 controls. The overall prev-Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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alence of protein C deficiency in the patients with venous
thrombosis was 8.3 percent (23 of 277 patients) (95% CI
5.4–12.4), as compared with 2.2 percent in the controls
(i.e. 3 of 138 subjects 95% CI 0.5–6.1; P < 0.05). Interest-
ingly, the relative risk (RR) estimate for thrombosis given
protein C deficiency was also close to 7 as in the case of
the family studies in Netherlands.
Both the work done by Heijboer et al and a subsequent
study by Tait et al estimated the population prevalence of
heterozygous protein C deficiency at 0.2% [41]. The rela-
tive risk for thrombosis among patients with protein C
deficiency was carried out by Koster et al involving 474
consecutive outpatients at anticoagulation clinics who
were excluded by age (greater than 70) and known malig-
nancy. The patients were asked to find their own controls
by sex, age and no known thrombotic disorder. The study
demonstrated the relative risk of thrombosis with protein
C deficiency to be at least 3.1 (95% CI 1.4–7) with reeval-
uation of patients with low levels increasing the RR to
closer to 4 [42].
There is marked variability in risk among families with
protein C deficiency that cannot be explained by the
genetic defect itself. In severely affected families, as many
as 75 percent of protein C-deficient individuals experience
one or more thrombotic events [43]; in other families, the
thrombosis rate is much lower. A risk factor for more
severe disease is the presence of a second thrombotic
defect, particularly factor V Leiden as will be discussed in
greater detail later on in the paper.
4. Protein S deficiency
Protein S serves as a cofactor for activated protein C. It was
originally discovered and purified in Seattle, leading to
the designation protein S. There are two homologous
genes for protein S: PROS1 and PROS2, which both map
to chromosome 3 [44].
In 2000, Gandrille et al identified 15 point mutations and
3 polymorphisms among 19 French patients; since then
mutations have been identified in 70 percent of protein S
deficient probands and a database of known protein S
gene mutations has been published [45]. As in the case
with the other inherited thrombophilias, there seem to be
few reports of large deletions causing the disorder. Three
phenotypes of protein S deficiency have been defined on
the basis of total protein S antigen concentrations, free
protein S concentrations, and protein S functional activ-
ity.
Type I – The classic type of protein S deficiency is associ-
ated with a decreased level of total S antigen (approxi-
mately 50% of normal), and marked reductions in free
protein S antigen and protein S functional activity [46].
Type II – This type of protein S deficiency is characterized
by normal total and free protein S levels, but diminished
protein S functional activity. Interestingly, all five muta-
tions originally described in these patients were missense
mutations located in the N-terminal end of the protein S
molecule, which includes the domains that interact with
activated protein C [47].
Type III – Also known as type IIa, this is characterized by
total protein S antigen measurements in the normal range
and selectively reduced levels of free protein S and protein
S functional activity to less than approximately 40 percent
of normal [48]. Interestingly, a case-control study by
Zoller in 1995 involving 327 Swedish families showed
that type I and type III are phenotypic variants of the same
genetic disease.
Protein S deficiency and risk of thrombosis
Protein S deficiency is inherited in an autosomal domi-
nant manner and is at least as common as antithrombin
and protein C deficiency [5]. The clinical manifestations
are similar to those seen with antithrombin and protein C
deficiency. Thrombosis occurs in heterozygotes whose
levels of functional protein S are in the range of 15–50%
of normal.
The prevalence of familial deficiency of protein S type I
among Caucasians, estimated from a large cohort of
healthy blood donors from the West of Scotland, is in the
range of 0.03 to 0.13 percent [49]. The prevalence is much
higher among individuals with established throm-
bophilia. In a Spanish study of 2132 consecutive unse-
lected patients with venous thromboembolism, 7.3
percent had protein S deficiency [50]. Based on these and
other studies, Martinelli et al estimated the lifetime prob-
ability of developing thrombosis among carriers of pro-
tein S deficiency was 8.5 times higher compared to those
with no defect.
In 1987, Engesser and colleagues conducted a study on 12
Swedish families with 136 members and found 71 of
them to be heterozygous for Type I protein S deficiency.
55% of those who carried the defect were found to have
had a thrombotic event and 77% of those were recurrent.
About half of the cases were precipitated by another con-
dition. They also showed that in phenotypic protein S
deficient families, the likelihood that affected family
members remain thrombosis-free at 45 years of age was
35 to 50 percent. This study showed a difference in rates
between men and women but was not able to provide an
adequate explanation in terms of difference in risk factors
between the two sexes [51].
Another study examined the incidence of thrombosis in
carriers in a Swedish family with a known missense muta-Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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tion (Gly295Val) [52]. Simmonds studied 122 members
in a family, with 44 of the members previously character-
ized for the specific gene defect in protein S. The study
showed little thrombotic risk before the age of 15 years.
On the other hand, the likelihood of being free of throm-
bosis by age 30 was only 50 percent compared to 97 per-
cent in normal family members. The odds ratio for
thrombosis in affected subjects was 11.5, and the study
showed that measurement of free protein S antigen levels
was predictive of the mutation and deficiency. In a UK
based family study with 28 index patients with protein S
deficiency, first degree relatives with the PROS1 gene
defect had a five-fold higher risk of thrombosis than those
with a normal gene and no other apparent thrombophilia
[53].
Overall, both family and cohort studies demonstrate that
like other thrombophilic disorders, heterozygous protein
S deficiency usually manifests in adulthood with a throm-
boembolic event. When present with other throm-
bophilias or when present in the homozygous form,
protein S usually presents in neonates with purpura fulmi-
nans [54].
5. Antithrombin deficiency
Antithrombin (AT) deficiency is a heterogeneous disor-
der. AT It is usually inherited in an autosomal dominant
fashion, thereby affecting both sexes equally. The first
database for antithrombin gene mutations was published
in 1991 and this has subsequently undergone various
revisions as newer mutations have been described. There
are different AT deficiencies based on the subtypes, as fol-
lows:
Type I – The type I deficiency state results from reduced
synthesis of biologically normal protease inhibitor mole-
cules [55]. In these cases both the antigenic and func-
tional activity of AT in the blood are reduced. The values
are reduced by approximately 50 percent in the heterozy-
gote. The 1997 antithrombin mutation database included
80 distinct mutations in patients with type I deficiency
[56]. The database shows that the molecular basis for this
disorder is usually a small deletion or insertion (less than
22 base pairs) or a deletion of a major segment of the AT
gene.
Type II – Type II AT deficiency is produced by a discrete
molecular defect within the protein. While the AT immu-
nologic activity is normal in this deficiency, plasma AT
functional activity is markedly reduced leading to risk of
thrombosis.
Type III – This type is characterized by normal functional
and antigenic antithrombin levels but impaired interac-
tion between AT and heparin [41].
Heparin binding site defect – Several abnormal AT mole-
cules have been identified with defects at a heparin bind-
ing site, resulting in isolated reductions in heparin
cofactor activity. These variants generally have mutations
at the amino-terminal end of the molecule [3]. Affected
individuals generally have plasma AT-heparin cofactor
activity measurements of approximately 50 percent and
normal progressive AT activity.
AT deficiency and risk of thrombosis
Congenital antithrombin deficiency is inherited as an
autosomal dominant trait. Affected patients have anti-
thrombin levels 40–60% of normal, and 70% of those
affected experience thrombo-embolic events before the
age of 50. Thrombotic episodes are rare before puberty in
AT-deficient individuals. They start to occur with some
frequency after puberty, with the risk increasing substan-
tially with advancing age [57].
In 1994, Tait et al studied 9,669 blood donors in Scotland
by taking blood samples and monitoring the donors for
two years. Of the study participants, 107 were found to
have an initial level of AT < 83 iu/dl. They were retested,
and eventually, 16 donors where found to have congenital
AT deficiency. The study suggested 1/600 or 1.65 per 1000
(95% CI of 0.95–2.27 per 1000). 2 of the affected individ-
uals had Type I deficiency while the other 14 had Type II.
Making corrections for donors who defaulted, the study
showed an overall prevalence of 1/4400 for Type I AT defi-
ciency and 1/630 for type II with an overall prevalence of
AT deficiency at 1/630 in the population studied. The
individuals with AT > 83 iu/dl after being retested is
explained by normal intra-individual and inter-assay var-
iation, but nevertheless brings into question the accuracy
of the testing. The authors themselves considered another
round of testing, but realized that that was not practical
with the large number of people tested. While selection
bias is obviously present, the authors felt that this was
minimal as their results were comparable to smaller stud-
ies done previously. They bring up the important issue of
whether the AT deficiency itself, or in combination with
other factors, would make a thromboembolic event likely
in these individuals. Another challenge when testing for
AT without other clinical information is that levels of anti-
thrombin can be reduced in protein-losing states. Marked
reductions in antithrombin levels occur in patients with
liver disease as well as severe malnutrition and these can
cause skewed results [58].
Using only an immunoassay for measuring plasma levels
of AT, initial estimates of the prevalence of AT deficiency
in the general Scottish population were one in 2000 to
5000. However, studies employing functional assays that
measure AT-heparin cofactor activity have found that the
prevalence of AT deficiency in the Scottish population isThrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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one in 250 to 500 [41]. The majority of AT-deficient
patients identified in these studies did not have a personal
or familial history of thrombosis and had a type II defect
with mutations at the heparin binding site. Among
patients with a first thrombotic event, the prevalence of
hereditary AT deficiency is approximately 0.5 to 1 percent,
being less common than factor V Leiden, the prothrombin
gene mutation, or protein S/protein C deficiency. A recent
study showed that homozygous children of consanguine-
ous parents who were asymptomatic carriers developed
severe venous or arterial thrombosis in association with
plasma AT-heparin cofactor levels below 10 percent of
normal [59].
The thrombotic risk associated with AT deficiency, as with
other inherited thrombophilias, has been assessed in two
ways: evaluation of patients with deep vein thrombosis
and evaluation of families with thrombophilia. In a Span-
ish study of 2132 consecutive unselected patients with
venous thromboembolism 12.9 percent had an anticoag-
ulant protein deficiency (7.3 percent with protein S, 3.2
percent with protein C, and 0.5 percent with anti-
thrombin). Similar findings were noted in a series of 277
Dutch patients with deep vein thrombosis: 8.3 percent
had an isolated deficiency of antithrombin, protein C,
protein S, or plasminogen compared to 2.2 percent of
controls [5]. In a study in 2001, five children from three
Austrian families had a homozygous antithrombin defi-
ciency type II affecting the heparin binding site (99 Leu to
Phe mutation). Four children had severe spontaneous
thromboembolic events (deep leg or caval vein thrombo-
sis, ischemic stroke) at one week, 3 months, 13 and 14
years of age. The fifth patient, a 17 year-old boy was
asymptomatic [60].
The absolute risk of thrombosis among patients with
inherited thrombophilia was evaluated by Martinelli et al
in 1998 in an Italian cohort study of 150 pedigrees con-
sisting of 1213 individuals. The study compared the risk
for thrombosis in individuals with inherited throm-
bophilia due to factor V Leiden, antithrombin, protein C,
or protein S deficiency [26]. The lifetime probability of
developing thrombosis compared to those with no defect
was 8.5 times higher for carriers of protein S deficiency,
8.1 for type I antithrombin deficiency, 7.3 for protein C
deficiency, and 2.2 for factor V Leiden. The selection of
patients was not solely based on their registration at the
thrombosis centers in Milan or Rome but also required
individuals to provide clinical evidence of thrombotic
events and hence increases the validity of the study.
6. Dysfibrinogenemia
The abnormal production of fibrinogen can result in dys-
fibrinogenemia. The abnormal fibrinogen usually exhibits
an abnormal thrombin-mediated conversion to fibrin. In
1984, Lijnen et al reported that the fibrin-mediated
enhancement of the activation of plasminogen by tissue-
type plasminogen activator observed with normal fibrin is
strongly decreased with the abnormal type known as
fibrin Dusard, although the binding of tissue-type plas-
minogen activator to the fibrin was normal. They sug-
gested that this impaired fibrin-mediated plasminogen
activation is most likely the cause of thrombophilia
among affected patients [61]. Over 300 examples from
unrelated families have been reported in the literature.
Over 90 percent of these cases are point missense muta-
tions, leading to the production of a dysfunctional protein
product. A website by Hanss and Biot started in 2001
maintains an updated version of all fibrinogen variants
with the last update showing 330 different mutations
[62]. Congenital dysfibrinogenemias are named after the
city where the patient was first identified or evaluated.
Roman numerals are added after the city name when there
are several dysfibrinogenemias from the same city (e.g.,
Caracas V). With rare exceptions, the mode of inheritance
of the congenital dysfibrinogenemias is autosomal domi-
nant.
Dysfibrinogenemia and the risk of thrombosis
While most patients with dysfibrinogenemia are clinically
asymptomatic, some present with a bleeding diathesis,
others with thrombophilia, and occasionally with both,
bleeding and thromboembolism. A study in 1990 by Hei-
jboer et al in this last group (i.e. those with both bleeding
and thromboembolism) showed the risk of thrombosis in
affected family members is much higher than in those
who are unaffected, suggesting that there is a true relation-
ship between certain dysfibrinogenemias and thrombosis.
A meta-analysis study looking at 9 studies put together the
various reported cases from the USA and different coun-
tries in Europe. They were unable to show a clear connec-
tion between dysfibrinogenemia and thrombosis [63]. A
study in Italy in 2000 demonstrated that missense muta-
tions in the beta-fibrinogen gene could cause congenital
afibrinogenemia by impairing fibrinogen secretion [64].
However, the exact mechanism of how abnormal fibrin
results in thrombosis is yet to be elucidated.
The prevalence of congenital dysfibrinogenemia in
patients with a history of venous thrombosis has been
estimated at 0.8 percent. The true prevalence of thrombo-
sis among patients with dysfibrinogenemia is unknown,
but is estimated to be around 10 to 20 percent [63].
7. Hyperhomocysteinemia
Hyperhomocysteinemia may be both a genetic and
acquired abnormality. Homocystinuria and hyperhomo-
cysteinemia can be caused by rare inborn errors of metab-
olism that result in marked elevations of plasma and urine
homocysteine concentrations.Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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Homocysteine is an amino acid derived from methionine.
Hyperhomocysteinemia occurs when increased amounts
of the amino acid accumulate in the blood due to of
impaired intracellular metabolism of homocysteine.
Homocysteine is metabolized by the body in two possible
pathways: transsulfuration, and remethylation. The trans-
sulfuration of homocysteine produces cysteine and the
reaction is catalyzed by cystathionine-β-synthase. This
process requires pyridoxal phosphate (Vitamin B) as a
cofactor. Remethylation of homocysteine produces
methionine. This reaction is catalyzed either by methio-
nine synthase or by betaine-homocysteine methyltrans-
ferase. Vitamin B12 (cobalamin) is the precursor of
methylcobalamin, which is the cofactor for methionine
synthase. Elevations in the plasma homocysteine concen-
tration can occur due to genetic defects in the enzymes
involved in homocysteine metabolism as well as due to
nutritional deficiencies in vitamin cofactors, or to other
factors including some chronic medical conditions and
drugs.
The most common form of genetic hyperhomocysteine-
mia results from production of a thermolabile variant of
methylene tetrahydrofolate reductase (MTHFR) with
reduced enzymatic activity (T mutation) [65]. The gene
encoding for this variant contains an alanine-to-valine
substitution at amino acid 677 (C677T) [66].
Homocysteinemia and the risk of thrombosis
In 1969, McCully demonstrated that premature athero-
sclerosis and arterial thrombosis is associated with severe
hyperhomocysteinemia [67]. Subsequent investigations
have confirmed this hypothesis, and it has recently
become clear that hyperhomocysteinemia is an independ-
ent risk factor for thrombosis. Although severe hyperho-
mocysteinemia is rare, mild hyperhomocysteinemia
occurs in approximately 5 to 7 percent of the general pop-
ulation [68].
In 1997 D'Angelo et al suggested that the genetic defect
may be present in 1.4–15% of Caucasians [69]. A meta-
analysis of 40 observational studies involving 11,162
patients who were homozygous for the thermolabile vari-
ant of MTHFR and 12,758 matched controls demon-
strated that patients with the MTHFR TT genotype had a
16 percent higher odds of coronary heart disease com-
pared with controls (odds ratio 1.16, 95% CI 1.05–1.28).
Den Heijer and colleagues have demonstrated that mild
hyperhomocysteinemia is an independent risk factor for
venous thromboembolism [70]. They found a marked
increase in the risk of venous thrombosis at the highest
plasma homocysteine concentrations. In their case-con-
trol study of 269 patients with a first, objectively diag-
nosed episode of deep vein thrombosis and 269 healthy
controls, 28 had plasma homocysteine levels above the
95th percentile for the controls, as compared with 13 of
the controls with a matched odds ratio of 2.5; 95 % CI:
1.2–5.2. They showed that a plasma homocysteine con-
centration of more than 22 μmol per liter increased the
matched odds ratio for deep venous thrombosis to 4.0.
Recently, Ridker et al showed that the combination of
hyperhomocysteinemia and factor V Leiden further
increases the relative risk of venous thromboembolism up
to 3.6-fold [71].
To investigate if homocysteine is a modifiable risk factor,
Bonna studied the effect of supplementation on homo-
cysteine levels as part of the Heart Outcomes Prevention
Evaluation (HOPE 2) investigation [72]. The study
showed that supplements combining folic acid and vita-
mins B6 and B12 did not reduce the risk of major cardiovas-
cular events in patients with vascular disease. Bonna also
suggested that homocysteine could be a marker, but not a
cause, of vascular disease. At the same time, Loscalzo
pointed out that while folic acid, vitamin B12, and vitamin
B6 change the homocysteine levels there is likely a com-
plex metabolic interactions involved that will need to be
explored further before any conclusions can be drawn
regarding homocysteine and the risk of thrombosis [73]
While there is evidence that hyperhomocysteinemia is
also a risk factor for venous thromboembolism (VTE,
there are conflicting data as to whether the risk of VTE is
markedly increased in patients when hyperhomocysteine-
mia is combined with an inherited thrombophilia [74].
8. Factor VII
In the coagulation pathway the association of factor VIIa
with tissue factor enhances the proteolytic activity by (1)
bringing the binding sites for both the substrate (factors X
and IX) and the enzyme (VIIa) into closer proximity and
by (2) inducing a conformational change, enhancing the
enzymatic activity of factor VIIa. There are several studies
that demonstrate that deficiency of factor VII can cause
significant increase in bleeding risk among affected indi-
viduals. There is also some evidence that elevated Factor
VII is related to an increased risk of thrombosis. The
Northwick Park Heart Study was a prospective study in the
early 1990s in which factor VII levels were found to be
strongly associated with thrombotic risk. The study
showed that fibrinolytic activity as measured by dilute
blood clot lysis time was associated with elevated factor
VII and increased the risk of fatal events among affected
patients [75].
9. Elevated Factor VIII
Elevated plasma factor VIII coagulant activity (VIII:C) is
now accepted as an independent marker of increased
thrombotic risk. In a population-based, case-control studyThrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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performed in the Netherlands by Koster et al in 1995,
individuals with factor VIII:C levels greater than 150 per-
cent of normal had an adjusted odds ratio of 4.8 for a first
episode of a venous thrombosis event compared to indi-
viduals with levels under 100 percent. In both this study
and an English study involving 46 patients referred for
evaluation of unexplained thrombosis, the incidence of
elevated factor VIII:C levels was approximately 25 percent
[76]. In a case-control study of 185 Dutch individuals,
Kraaijenhagen et al looked at different levels of factor VIIIc
and the associated risk of thrombosis. They found an odds
ratio of thromboembolism for factor VIIIc > 200IU/dl as
high as 11 (95%CI 2–71) for a single episode and 45
(95% CI: 6–370) for recurrent episodes of thromboembo-
lism. The study demonstrated factor VIIIc as an independ-
ent risk factor for thrombosis. Kraaijenhagen et al also
suggested there was a direct relationship between the
degree of increase of factor VIII and the risk of thrombosis
[77].
10. Elevated Factor IX
The previous section described how elevated plasma lev-
els of factor VIII (> 150 IU/dL) are an important risk factor
for deep vein thrombosis. Factor VIII is the cofactor of fac-
tor IXa in the activation of factor X and hence, it has been
postulated that elevated levels of factor IX can also
increase the risk of thrombosis [78]. Factor IX is a circulat-
ing serine protease that serves as an essential component
of the blood coagulation pathway, and has been shown to
increase with age in humans [79]. A study was conducted
in 2000 involving 426 Dutch patients with a first, objec-
tively-diagnosed episode of DVT compared to 473 popu-
lation controls. This study was part of a large population-
based case-control study on risk factors for venous throm-
bosis, the Leiden Thrombophilia Study. Using the 90th
percentile measured in control subjects (P[90] = 129 U/
dL) as a cutoff point for factor IX levels, van Hylckama
Vlieg et al found a 2- to 3-fold increased risk for individu-
als who have factor IX levels above 129 U/dL compared
with individuals having factor IX levels below this cutoff
point [80]. After exclusion of individuals with known
genetic disorders, they found an odds ratio of 2.5 (95%
confidence interval: 1.6–3.9). These results show that an
elevated level of factor IX is a common risk factor for
thrombosis among the Dutch population.
11. Elevated Factor XI
Factor XI, a component of the intrinsic pathway of coagu-
lation, contributes to the generation of thrombin, which
is involved in both the formation of fibrin and protection
against fibrinolysis. Looking at genetic data from the Lei-
den Thrombophilia Study based in the Netherlands, using
474 cases and 474 controls, the authors compared indi-
viduals who had a factor XI level above the 90th percentile
to those who had levels below that level. The age- and sex-
adjusted odds ratio for deep venous thrombosis was
found to be 2.2 (95 % CI: 1.5–3.2). As is the case with fac-
tor VIII, this study suggested that the degree of elevation
of factor XI correlates with risk of venous thrombosis [81].
12. Factor XII deficiency
Factor XII or Hageman factor (named after the first patient
found to have this deficiency) is the zymogen of a serine
protease that initiates the contact activation reactions and
intrinsic blood coagulation in vitro. Severe factor XII defi-
ciency (factor XII activity less than 1 percent of normal) is
inherited as an autosomal recessive trait. Affected patients
have marked prolongation in the activated partial throm-
boplastin time (aPTT) and increased thrombotic tendency
likely due to reduced plasma fibrinolytic activity. Evaluat-
ing 14 Swiss families in 1991, Lammle et al demonstrated
that homozygous factor XII deficiency may be associated
with an increased risk for venous thromboembolic dis-
ease. However, they suggested that partial factor XII defi-
ciency was not, by itself, a strong risk factor for
thrombosis [82]. In 2004, Girolami et al looked at
reported cases of homozygous factor XII deficiency among
Italian patients and noted 11 cases of venous thrombosis
had been described. All but four of the cases were noted to
be associated with various other risk factors such as preg-
nancy, the postpartum period, surgery, trauma, AT defi-
ciency, or, heterozygous factor V Leiden. They concluded
that the role played by FXII deficiency in the pathogenesis
of venous thrombosis is minor, if any [83].
13. Elevated Lipoprotein a
Lipoprotein a (Lp a) is an inherited risk factor for throm-
boembolism [84]. Lp (a) inhibits the binding of plas-
minogen to the cell surface, reducing plasmin generation
and subsequent clot lysis. In 2001, Caplice et al demon-
strated that along with its antifibrinolytic mechanism of
action, Lp (a) also binds and inactivates TF-pathway
inhibitor, which is a major endogenous regulator of tissue
factor (TF)-mediated coagulation [85]. A case controlled
study based on Germany by von Depka et al in 2000 of
603 patients and 430 healthy adults showed an independ-
ent association between elevated levels of lipoprotein a (>
300 mg/L) and venous thromboembolism (95% CI: 1.4–
3.2 with p value 0.002) [86]. Another study in Germany
around the same time showed that 186 children with a
history of venous thrombosis had a significantly higher
median Lp(a) level (19 versus 4.4 mg/dL) than the same
number of control subjects. The risk for thromboembolic
events in children with Lp(a) levels in the upper quartile,
ie, > 30 mg/dL, was 7.2 (95% CI, 3.7 to 14.5) [87].
14. Platelet glycoprotein gene polymorphisms
Being a critical element of the clot forming process, plate-
lets and platelet glycoprotein gene polymorphisms have
received increasing attention as possible inherited deter-Thrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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minants of prothrombotic tendency. However, their role
in genetic susceptibility to thrombotic disease remains
controversial. Reiner et al suggested in 2001 that the glyc-
oprotein IIIa Leu33Pro amino acid substitution was asso-
ciated with a subtle effect on platelet thrombogenicity in
vitro. The Leu33Pro allele seems to cause structural
changes in the GPIIb/IIIa receptor which may in turn lead
to a different ligand binding of the active GPIIb/IIIa recep-
tor. However, Reiner et al concluded that it is not a major
risk factor for arterial thrombotic disease among the gen-
eral population [88]. Platelet collagen receptor (glycopro-
tein Ia/IIa; integrin alpha2 beta1) polymorphisms have
also been implicated in thrombotic disease [89]. More
studies need to be done to establish a relationship
between the risk of thrombotic events and platelet glyco-
protein gene polymorphisms.
15. Plasminogen Deficiency
Two major components of the fibrinolytic system are plas-
minogen and tissue-type plasminogen activator (tPA).
Plasminogen is converted to the active enzyme plasmin
by tPA in the presence of fibrin. Plasmin, in turn, digests
the fibrin clot, forming soluble fibrin degradation prod-
ucts. A deficiency of either tPA or plasminogen could
reduce the capacity to remove excessive clot and contrib-
ute to thromboembolic disease [90].
In 1978, Aoki et al identified the first case of an abnormal
plasminogen [91]. In a large multi-center study in 1997,
Mateo et al looked at plasminogen levels in over 2000
Spanish patients presenting with venous thrombosis.
Their studies suggested that plasminogen deficiency
occurs in 0.5% to 2.0% of patients with a history of
thrombosis, a frequency similar to that of antithrombin
deficiency in the same populations. On the other hand, in
a survey of 53 Swiss family members of 23 plasminogen-
deficient patients, Demarmels et al found that 5 (18%) of
28 family members with plasminogen deficiency had a
history of thrombosis, whereas 5 (20%) of 25 family
members with normal plasminogen levels also had a his-
tory of thrombosis. Although there is no apparent differ-
ence in the rate of thrombosis between those with and
without plasminogen deficiency, the overall rate of
thrombosis in family members in this study was high.
This could be in part due to the presence of additional risk
factors for thrombosis, such as factor V Leiden [92].
There are both quantitative defects (type I, hypoplasmino-
genemia in the heterozygote and aplasminogenemia in
the homozygote) and functional defects (type 2, dysplas-
minogenemia) with plasminogen deficiency. Thrombosis
has been reported in young patients when the plasmino-
gen concentration is less than 40 percent of control val-
ues. The development of ligneous conjunctivitis,
hyperviscosity of tracheobronchial and nasopharyngeal
secretions, impaired wound healing, and hydrocephalus
soon after birth have been reported in a German patient
with homozygous plasminogen deficiency [93].
16. Tissue Plasminogen Activator (tPA)
In a multi-center, randomized trial in 1996, Schulman
and Wiman evaluated the relationship between various
fibrinolytic parameters and the incidence of recurrent
thrombosis among nearly a thousand Swedish patients
with venous thrombosis [94]. They noted that there was
no significant difference in the absolute values of tPA
between those patients who did and did not have recur-
rent thrombosis. However, a higher percentage (50% vs
36%, P < .001) of patients in the group with recurrent
thrombosis had a tPA level above the upper limit of nor-
mal (10 ng/mL) than in the patients without recurrent
thrombosis. The authors concluded that increased levels
tPA antigen in patients with venous thrombosis correlate
with development of recurrent thromboembolic events
within the following 3–6 years. One of the main limita-
tions of the study was that one could not determine the
degree of risk of a thromboembolic event for a patient
with elevated tPA [94].
17. Plasminogen activator inhibitor (PAI)
PAI- type 1 (PAI-1) inhibits tissue plasminogen activator
(tPA). High levels of PAI-1 may be associated with an
increased risk of arterial thrombosis due to inhibition of
fibrinolysis [95]. Overall, the data available on the rela-
tionship between PAI-1 and the risk of thrombosis is con-
flicting. In 1996, Schulman and Wiman studied over 900
Swedish patients over 6 months after their initial presen-
tation with a thrombotic event and found that elevated
PAI-1 levels correlated with the risk of recurrence [94].
Using a cutoff level of 300 U/mL, 18% of subjects with
recurrence had a higher level compared with 12% at a
lower level (P = .045). In 2001, Crowther et al performed
a prospective cohort study of 303 Canadian patients with
a first episode of venous thromboembolism [96]. They
conducted fibrinolytic testing and followed the patients
for up to 3 years for recurrence. There was no clear differ-
ence in PAI-1 plasma levels in patients who did, or did
not, suffer recurrence. There was no observed difference in
levels between subjects who had idiopathic thrombosis
compared to those with thrombosis in relation to another
risk factor.
18. Thrombomodulin gene defect
Thrombomodulin is a major component of the protein C
anticoagulant pathway. The protein C anticoagulant com-
plex consists of thrombin (factor IIa) as the enzyme,
thrombomodulin as the cofactor, and protein C as the
substrate. As clot formation progresses, thrombin binds to
thrombomodulin, an integral membrane protein on the
endothelial cell surface [97]. Binding of thrombin toThrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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thrombomodulin induces a conformational change in
thrombin, which changes its substrate specificity such that
it acquires the ability to activate protein C and no longer
promotes platelet activation or the cleavage of fibrinogen.
A gene defect in the production of thrombomodulin will
also affect the protein C anticoagulant pathway and will
predispose an individual to thrombosis. However, bio-
chemical detection of thrombomodulin defects is ham-
pered by the location of the protein in the endothelial cell.
The first mutation of thrombomodulin was diagnosed by
Ohlin et al in 1995 in a 45 year-old male presenting with
pulmonary embolism. Both the man and his healthy 21
year-old son were found to carry a heterozygous thrombo-
modulin gene substitution of G1456 to T [98]. Further
investigations by Ohlin et al have found 8 heterozygous
point mutations in 300 Swedish patients with throm-
boembolic disease [99]. The authors were able to show a
statistically significant difference in allelic frequency
between healthy and affected patients (p < 0.004) despite
the small sample size.
19. Heparin Cofactor II
Heparin cofactor II (HC II) is a specific inhibitor of
thrombin in the presence of heparin or dermatan sul-
phate. Studies in mice suggest an increased likelihood that
HCII might inhibit thrombosis following arterial injury.
In 1987, Bertina et al studied 277 Dutch patients with a
history of unexplained venous thrombosis and identified
three patients with a HC II below the lower limit of the
normal range (60%) [100]. Family studies demonstrated
hereditary HC II deficiency in two of the three cases.
Among the 9 heterozygotes for HC II deficiency only one
patient had a well-documented history of unexplained
thrombosis. This and other studies suggest that although
there have been reports on families in which a hetero-
zygous HC II deficiency is associated with thromboem-
bolic events, heterozygous HC II deficiency is as prevalent
among healthy subjects as it is among patients with deep
venous thrombosis [101]. It is, therefore, not yet clear
whether HC II is, or is not, a thrombotic risk factor. Villa
et al described a Spanish patient in 1999 who was found
to be homozygous for HC II deficiency after suffering sev-
eral thrombotic events [101]. Study of the patient's family
showed that both the patient and her sister had
homozygous HC II deficiency and that 12 of the 27 family
members had heterozygous HC II deficiency. The patient
was also found to have mild AT deficiency. Interestingly,
all the 12 family members who were heterozygous for the
deficiency, and the patient's sister, who was homozygous
for HC II deficiency, were found to be healthy. The
authors suggested that HC II deficiency may not play a
limited in-vivo role as a thrombotic risk factor unless asso-
ciated with AT deficiency or another congenital throm-
botic risk factor.
20. Histidine-rich glycoprotein deficiency
Histidine-rich glycoprotein (HRG) is a single-chain glyco-
protein. Platelets store HRG in the α-granules and secrete
it upon thrombin activation. HRG has been shown to
interact with plasma proteins involved in blood coagula-
tion and fibrinolysis, however, the physiologic signifi-
cance of molecular interactions is unclear [102].
Histidine-rich glycoprotein deficiency related to throm-
bophilia was first described in 1993 in a 43-year-old oth-
erwise healthy Japanese woman who suffered from right
transverse sinus thrombosis during oral contraceptive
treatment [103]. Over the 6 months after stopping the
drug, her plasma activities of antithrombin, protein C,
protein S, heparin cofactor II, plasminogen and plasmino-
gen activator inhibitor were normal, but her plasma histi-
dine-rich glycoprotein (HRG) level was only 21% of the
normal level of 109.5 +/- 51.5% (mean +/- 2 SD). Low lev-
els of plasma HRG (20% to 35% of normal) were also
found in her aunt, uncle and two daughters. Further anal-
ysis of the patient by Shigekiyo et al in 1998 demonstrated
that a single missense mutation (nucleotide G429 to A in
exon 3) leading to a mutation of Gly85 to Glu in the HRG
molecule is a genetic cause for the first case of congenital
HRG deficiency. At this time, further studies need to be
carried out to determine the exact mechanism of HRG
deficiency in thrombosis and the risk associated with indi-
viduals who are HRG deficient.
Combined deficiencies
The varying degrees to which family members carry a cer-
tain defect has raised the possibility of individuals carry-
ing more than 1 defect being more susceptible to
thromboembolic events. In 1998, Mustafa et al suggested
that there appeared to be an increased incidence of a sec-
ond thrombophilic defect, particularly factor V Leiden,
among patients who presented with thrombosis and were
primarily found to have deficiencies of protein S or pro-
tein C [104]. In a study in Austria, factor V Leiden was
present in four of fourteen patients with protein S defi-
ciency and six of fifteen with protein C deficiency [104].
Carriers of two defects seem to be at a higher risk for
thrombosis than their relatives with a single defect. In
1995, Koelman et al showed that APC-R was an additional
risk factor for Dutch patients with protein C defi-
ciency[105]. They found that 73% of the family members
who had factor V Leiden combined with the protein C
deficiency experienced a thromboembolic event, com-
pared with 31% and 13% of carriers with a single defect of
protein C deficiency or factor V respectively. In a retro-
spective case-control study in 2000, Gandrille studied 113
French individuals with known protein C deficiency and
carried out genetic tests to determine presence of factor V
Arg-Gln mutation [47]. 14% of those with protein C defi-
ciency were found to have factor V mutation compared to
1% of the normal individuals. This and other studies haveThrombosis Journal 2006, 4:15 http://www.thrombosisjournal.com/content/4/1/15
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demonstrated that the simultaneous occurrence of hered-
itary thrombophilias and prothrombotic polymorphisms
can substantially increase the risk of thromboembolic
events in patients. In Germany, Boven et al studied 128
families in 1996 with AT deficiency and found that an
additional factor V defect increased the likelihood of hav-
ing a thromboembolic event at a younger age [106]. In
individuals with both defects, the percentage of sympto-
matic individuals with both abnormalities was 80%. In
1999, Salomon et al published a casecontrol study of 162
Israeli patients with at least one episode of venous throm-
boembolic disease compared with 336 healthy controls
[107]. Two or more polymorphisms were detected in 27
of 162 patients (16.7%) and in 3 of 336 controls (0.9%).
The authors of the study demonstrated an odds ratio of
58.6 (confidence interval [CI], 22.1 to 155.2) for joint
occurrence of factor V and prothrombin gene polymor-
phisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR
polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II
and MTHFR polymorphisms. They concluded that, in the
study population, the presence of greater than one of the
prothrombotic polymorphisms was associated with a sub-
stantial risk of venous thromboembolism.
In 2001, Emmerich et al conducted a pooled analysis of 8
case control studies looking at 2310 cases and 3204 con-
trols to estimate the risk of thrombosis in double hetero-
zygotes for factor V Leiden and the prothrombin
G20210A mutations [108]. Among the population stud-
ied, 12% percent of those heterozygous for factor V Leiden
were also heterozygous for factor II G20210A, while 23%
of patients heterozygous for factor II G20210A were also
heterozygous for factor V Leiden. The data showed an
odds ratio for venous thrombosis in double heterozygotes
of 20.0 (11.1–36.1). This was much higher than the odds
ratios for thromboembolism of 4.9 (95% CI; 4.1–5.9) for
the factor V Leiden and 3.8 (3.0–4.9) for the factor II
G20210A mutation as single defects [108].
Conclusion
The risk of thrombosis in the pediatric population is less
than that in adults. However, thromboembolic disease
represents a significant source of mortality and morbidity,
and venous thromboembolism continues to present a
challenge to clinicians. It is important to note that there
are various settings such as surgery, flights etc. that can
lead to thrombosis in otherwise healthy individuals who
have thrombophilic defects. In recent years, there have
been major advances in our understanding of congenital
defects that predispose to thrombosis. This has led to a
more complete understanding of the disease processes, as
well as recommendations for appropriate screening,
detection, diagnosis and treatment.
Current treatment for thrombophilias involves both
prophylaxis with low-molecular-weight heparin and treat-
ment involving heparin, warfarin or purified factor con-
centrate. The presence of an inherited thrombophilia
should not alter the intensity of anticoagulant therapy,
given that antithrombin, protein C, or protein S defi-
ciency, factor V Leiden, and the prothrombin G20210A
mutation are not unusually anticoagulant resistant. How-
ever, they can increase the optimal treatment duration
after a first thromboembolic event [109].
Clinical trials on treatment are essential since they will
provide physicians with the information to determine
whether or how they should modify their clinical practice.
Correctly identifying hereditary risk factors, together with
appropriate genetic evaluation and counseling, will allow
the informed patient and physician to work together for
effective management of thrombophilia and prevention
of subsequent thrombotic events.
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